Skip to content
Subscriber Only
Business
Prognosis

CureVac’s Flop Shows Pfizer, Moderna Made mRNA Look Too Easy

  • German firm’s technology, dosing differ from Pfizer, Moderna
  • Proliferation of variants has complicated studies since 2020
Bloomberg business news
A Race to Vaccinate the World
Updated on

The rapid development and remarkable efficacy of Covid-19 shots from Pfizer Inc. and Moderna Inc. created sky-high expectations for the novel technology they employ. CureVac NV’s vaccine disappointment shows that not every messenger-RNA project will live up to hopes.

The German biotech firm made some crucial choices that set its candidate apart. Although the trial results it published earlier this week aren’t directly comparable, and the proliferation of viral variants has complicated studies since the other shots were tested last year, experts say key differences between the vaccines probably played a major role in CureVac’s weak results.